Two cDNAs encoding novel isoforms of Xenopus laevis melatonin receptors were cloned using PCR primers specific for the X. laevis-melanophore Mel 1c melatonin receptor described in a recent publication. The novel isoforms were highly homologous to the described frog Mel 1c cDNA, although the C-terminal tail of both was shorter by 65 amino acid residues. Nucleotide sequences of these novel isoforms, called Mel 
INTRODUCTION
Melatonin is involved in a variety of physiological processes including biological rhythms, seasonal breeding, pigment condensation, and neuroendocrine function (1, 2) . This hormone exerts its functions through specific receptors (3) whose corresponding cDNA sequences have been isolated recently in various animal species and humans (4) (5) (6) . The amino acid sequence of these receptors indicates that they belong to the seven-transmembrane domain receptor family. All cloned melatonin receptors have been reported to be coupled to pertussis toxin-sensitive proteins and to inhibit adenylyl cyclase, suggesting the involvement of G i proteins. Recently, stimulation of cAMP accumulation of type II adenylyl cyclase through G i and G z proteins has been shown for the melatonin receptor from Xenopus dermal melanophores in transient expression experiments (7) . Previous studies have suggested that second messengers, other than cAMP, might be modulated by melatonin, but a clear picture of the spectrum of biochemical signals elicited by melatonin is still lacking (2, 3) . In addition, no data on multiple signaling pathways are available so far from experiments reported with cloned melatonin receptors.
The first melatonin receptor cDNA cloned from Xenopus dermal melanophores was reported to contain a C-terminal tail that was 65 residues longer than that of all other cDNAs of melatonin receptors subsequently characterized in mammals and birds. Thus, this study was conducted to isolate a potential shorter melatonin receptor cDNA form from Xenopus that might be equivalent to that found in other species.
Messenger RNA encoding such a short receptor is indeed present in Xenopus skin. In addition, we identified a second highly homologous coding region, which is likely to correspond to an allelic isoform of the short melatonin receptor.
The two putative alleles, which differ by 35 nucleotides and six amino acid residues, modulated intracellular cAMP and cGMP in a dose-dependent manner but with different efficiencies. One of the two alleles was not capable of promoting the inhibition of adenylyl cyclase in one of three cell lines transfected with the corresponding cDNA. The second allele displayed a weaker coupling with the cGMP pathway in all cell lines.
RESULTS

Cloning of Melatonin Receptor cDNAs
Several pairs of PCR-primers were selected based on the sequence of a melatonin receptor cDNA isolated from immortalized melanophores of X. laevis (4) . These primers were used in RT-PCR reactions to amplify overlapping cDNA fragments from X. laevis skin mRNA (Fig. 1) . Three amplified fragments that spanned the coding region from the N terminus to Ala349 were obtained ( Fig. 1, fragments 1-3 ). However, all attempts failed to amplify the last portion of the coding region and the downstream 3Ј-untranslated region. This missing 3Ј-region could be amplified only with a poly T-containing oligonucleotide as lower primer. Two different 3Ј-fragments of Ϸ400 bp (short) and of Ϸ600 bp (long) were obtained with this approach (see Fig. 1 , fragment 4). The nucleotide sequences of both fragments were identical until just before the poly A tail of the short fragment. Whereas the short fragment continued with its poly A tail, the long fragment continued with an additional 162 nucleotides before its own poly A tail (Fig. 2B ). Amplification products derived from different independent PCRs were cloned and characterized by enzymatic digestion and dideoxy sequencing (four to six individual clones for each fragment).
All clones of fragment 1 were 100% homologous to the known Xenopus Mel 1c sequence. Among clones of fragments 2 and 3, some were identical to the published sequence while others showed changes in the nucleic acid sequence. In the variant of fragment 2, two silent nucleotide substitutions were found, whereas variants of fragment 3 contained 26 silent nucleotide substitutions and six substitutions causing a change of the corresponding amino acid residue (Fig. 2) . Both long and short forms of fragments 4 were highly homologous to the sequence of Xenopus melatonin Mel 1c receptor up to Met-353 (identical or with a single silent substitution). However, in the six independent clones we analyzed, the two amino acid substitutions after the Met-353 (Leu-354 3 Tyr and Gly-355 3 Val) preceded a stop codon that shortened the C-terminal tail by 65 amino acid residues ( Fig. 2A) . Short and long 3Ј-noncoding regions were identical up to the polyadenylation signal of the shorter form (Fig.  2B) .
Finally, the entire melatonin receptor cDNA could be amplified from Xenopus skin cDNA in a single PCR reaction using the N-terminal upper primer 3S and the lower primer 12AS located in the newly identified 3Ј-noncoding region (see Fig. 1 ). Restriction analysis of several independent clones confirmed that the two different melatonin receptor mRNAs were indeed present in our samples and that the substitutions found in fragments 2-4 belonged to a single mRNA species. Both mRNAs encoded proteins of 354 amino acids, which were most similar to the chicken Mel 1c receptor among cloned melatonin receptors (78% homology). Therefore, the receptor form without any substitution other than the shortened C terminus was called Mel 1c (␣) , whereas the form with multiple substitutions was called Mel 1c (␤) .
Characterization of the Mel 1c -Locus in Various Xenopus Species
Highly homologous Mel 1c(␣) and Mel 1c(␤) receptors could represent either two alleles at the same genomic locus or two isoforms encoded by different genes. To address this question, fragment 3 of Mel 1c receptors was amplified by PCR from genomic DNA in 43 X. laevis individuals. Several of these animals were inbred, while others were wild animals directly imported from South Africa. Amplified DNA fragments of the expected size were digested with appropriate restriction enzymes specific for either Mel 1c(␣) and Mel 1c(␤) cDNAs (Fig. 3) . In one X. laevis (ff) individual, homozygous for the major histocompatibility complex and other genetic markers (8) , only the Mel 1c(␣) receptor gene was found. PCR analysis of a second X. laevis (rf) frog, known to be heterozygous for the genetic markers mentioned above, revealed the presence of both Mel 1c(␣) and Mel 1c(␤) receptor genes (Fig. 3) . This observation supports the hypothesis that the two melatonin receptor isoforms are encoded by the same genomic locus. Analysis of the other 41 animals The PCR amplification used in this study corresponds to fragment 3 of Fig. 1 showed the presence of either both receptor genes (40 individuals) (Fig. 4A ), values that are in good agreement with those determined for other high-affinity melatonin receptors, including that cloned previously from X. laevis melanophores (4, 10). Competition experiments showed that the rank order of affinity for several ligands was characteristic of melatonin receptors ( Fig. 4B and Table 1 ) (10) . No significant differences were found between Mel 1c(␣) and Mel 1c(␤) receptors in binding experiments.
Modulation of cAMP Accumulation
High-affinity melatonin receptors are known to mediate the inhibition of adenylyl cyclase activity (4, 11) . As expected, in Ltk Ϫ cells expressing the Mel 1c(␣) receptor, melatonin promoted the inhibition of forskolinstimulated cAMP accumulation (Fig. 5 ). The IC 50 value of this effect was approximately 6 ϫ 10 Ϫ10 M, in good agreement with values reported for high-affinity melatonin receptors (3, 4) . Surprisingly, in cells expressing the Mel 1c(␤) receptor, such an effect was not observed even at concentrations of melatonin up to 0.1 mM. Similar observations were made on two additional Ltk Ϫ clones. Basal levels of cAMP were not affected by melatonin in either cell line even in the presence of 3-isobutyl-1-methylxanthine (IBMX). Inhibition of cAMP accumulation by melatonin receptors is mediated by ␣-subunits of G i proteins (12) . To eliminate the possibility that the impaired signaling of Mel 1c(␤) receptor was due to quantitative changes of G i␣ subunits, control Ltk Ϫ cells and clones expressing either Mel 1c(␣) or Mel 1c(␤) receptors were compared for their G i␣ subunit content. Western blot analysis with a specific antibody recognizing all three subtypes of G i␣ (13) could not detect major quantitative differences (data not shown).
Signal transduction was also studied after transient transfection of both Mel 1c cDNA isoforms in Ltk Ϫ cells to exclude a potential artifact associated with clonal selection. Ltk Ϫ cells were cotransfected with human ␤ 2 -adrenergic receptor (␤ 2 AR) cDNA and either Mel 1c(␣) or Mel 1c(␤) receptor cDNA; the coexpression of different receptors allows selective study of the subpopulation of cells that has internalized the exogenous DNA (14) . Three days after transfection, cells were studied for the melatonin-dependent inhibition of cAMP accumulation in response to the ␤ 2 AR agonist isoproterenol and for the number of ␤-adrenergic and melatonin binding sites (Fig. 6) . No binding sites for either receptor could be measured in wild type control cells. In cells transfected with the ␤ 2 AR cDNA alone, isoproterenol incubation resulted in a 5-fold increase of cAMP. In cells cotransfected with identical amounts (1 g plasmid DNA) of Mel 1c(␣) and ␤ 2 AR receptor cDNAs, simultaneous incubation with isoproterenol and melatonin resulted in a significantly reduced accumulation of cAMP (65 Ϯ 5% of control, P Ͻ 0.05) (Fig. 6 ). Under the same conditions, Mel 1c(␤) receptors were not able to inhibit isoproterenol-induced cAMP accumulation, despite the expression of an equivalent number of receptor-binding sites. Similar results were obtained when Mel 1c(␤) receptor cDNA was in 10-fold excess over ␤ 2 AR receptor cDNA (data not shown).
Modulation of cAMP accumulation was further examined in two other cell lines, human embryonic kidney 293 (HEK 293) cells and HeLa cells stably transfected with Mel 1c(␣) or Mel 1c(␤) cDNA. Clones expressing between 100 and 800 fmol receptor/mg protein were selected for these studies. Interestingly, both receptor isoforms promoted the inhibition of forskolin-stimulated cAMP accumulation in both cell lines (Fig. 7) 
Modulation of cGMP Accumulation
Modulation of cGMP content has been proposed as an additional signaling pathway for melatonin receptor (15) . Ltk Ϫ cells, HEK 293 cells, and HeLa cells expressing either Mel 1c(␣) or Mel 1c(␤) receptors were incubated with melatonin, and subsequent effects on intracellular cGMP were analyzed. Melatonin (up to 10 M) had no effect on basal cGMP levels in either cell line. Intracellular cGMP content depends on the opposite activities of guanylyl cyclases, which synthesize cGMP, and of phosphodiesterases (PDE), which degrade cGMP. The PDE inhibitor IBMX was included in the assay to block cGMP degradation by PDE. Under these conditions the cGMP level increased approximately 3-, 2-, and 5-fold in unstimulated Ltk Ϫ , HeLa, and HEK 293 cells, respectively, indicating the presence of a basal PDE activity in these cell lines. Incubation with melatonin inhibited IBMX-promoted accumulation of cGMP, in a dose-dependent manner, in all three cell lines expressing either Mel 1c(␣) or Mel 1c(␤) receptors (Fig. 8) tion of cGMP was modest, inhibition of cGMP accumulation was not significant, revealing the limitations of this assay. Melatonin stimulation of mock-transfected cells did not affect the cGMP increase promoted by IBMX.
Guanylyl cyclases are subdivided into two major families, soluble guanylyl cyclases, which are stimulated by NO, and membrane-bound guanylyl cyclases, which are stimulated by extracellular peptide ligands such as atrial natriuretic peptide (ANP). IBMX-promoted cGMP accumulation could be attributed to a soluble guanylyl cyclase activity in HEK 293 cells because this effect was specifically inhibited by the soluble guanylyl cyclase inhibitor 1H-(1,2,4)oxadiazolo(4,3-␣)quinozalin-1-one (ODQ) (16, 17) (Fig. 9A) . The existence of a soluble guanylyl cyclase activity was further confirmed by an significant increase in cGMP levels by the NO donor nitroprusside, which was completely blocked by ODQ. Neither basal nor ANP-stimulated membrane-bound guanylyl cyclase 
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Vol 11 No. 8activity was detectable. Soluble guanylyl cyclase was directly activated by nitroprusside in the absence and presence of increasing melatonin concentrations (Fig.  9B) . Although melatonin decreased nitroprussidestimulated cGMP accumulation slightly, no dose-dependent inhibition was observed in the relevant concentration range between 10
Ϫ12
and 10
Ϫ5
M melatonin, suggesting no direct effect of melatonin receptor signaling on soluble guanylyl cyclase. Pertussis toxin, which catalyzes the inactivating ADP ribosylation of G i/o␣ subunits of G proteins, has been shown to block the G i -mediated inhibition of cAMP accumulation promoted by melatonin receptors (18, 19) . Preincubation with pertussis toxin abolished the effect of melatonin on cGMP accumulation, suggesting that this signaling pathway is G i/o mediated (Fig. 9C) .
DISCUSSION
The cDNAs of two novel isoforms of X. laevis melatonin receptors, Mel 1c(␣) and Mel 1c(␤) , were cloned from skin mRNA by RT-PCR. These receptors could be classified, based on their high homology with previously identified melatonin receptors in the Mel 1c subfamily (5, 6). Both receptors displayed a predicted C terminus that was shorter by 65 amino acids than previously described for the X. laevis Mel 1c receptor cloned from an immortalized dermal melanophore cell line (4). Additional nucleotide changes were found in the Mel 1c(␤) receptor that did not correspond to any of the PCR amplification products from Xenopus recently reported by Reppert et al. (6) . These differences are unlikely to be due to errors caused by the amplification procedure used here because several independent RT-PCR reactions, performed with a high-fidelity Pfu DNA polymerase, yielded the same results. Errors due to reverse transcription may also be excluded because the same nucleotide changes were found in PCR products amplified from genomic DNA of 41 frogs.
We believe that Mel 1c(␣) and Mel 1c(␤) receptors described here are likely to be the true Mel 1c receptor subtypes expressed in X. laevis skin: 1) both receptors are identical in length to all other melatonin receptors reported so far (5, 6); 2) no amplification products could be obtained using several antisense PCR primers located in the 3Ј-coding region of the sequence published previously; 3) PCR reactions, targeted at the 3Ј-end of the coding region and at the next untranslated region using a nonspecific oligo dT primer, did not amplify other DNA fragments than those corre- X. laevis Mel 1c(␣) and Mel 1c(␤) melatonin receptors are more than 98% homologous at the protein level. This high homology suggests that these two isoforms are alleles rather than subtypes encoded by different genes. To address this question, the PCR amplification products from genomic DNAs of 43 animals (including 12 wild individuals) were analyzed using discriminating restriction enzymes. Forty-one DNAs contained the two forms of Mel 1c genes, whereas in two individuals only the Mel 1c(␣) DNA could be amplified. Interestingly, one of these two latter frogs was known to be homozygous for the histocompatibility locus and for other genetic markers. Southern blot analysis of genomic DNA of three individuals, two containing the two Mel 1c -isoforms, according to PCR analysis, and one individual containing only the Mel 1c(␣) DNA, revealed in each case the presence of four hybridization signals using a probe of exon II under high stringency conditions. Two factors might contribute to the detection of several hybridization signals: 1) Reppert et al. (6) have PCR-amplified three amplification products from Xenopus genomic DNA, whose sequence corresponds to three closely related members of the melatonin receptor family; 2) Xenopus is known to have duplicated its genome during evolution followed by partial genomic deletions, thereby generating several copies of the same locus embedded in different genomic contexts. Taken together Comparison of the pharmacological profiles of the three receptor isoforms, Mel 1c(␣) and Mel 1c(␤) and the reported longer version, does not reveal any signifi-cant difference. This is not surprising since amino acid residues located in the putative transmembrane regions, and not in the intracellular domains, are predicted to be involved in ligand binding (22, 23) .
The Mel 1c(␣) receptor mediated inhibition of forskolin-stimulated cAMP accumulation in three different cell lines in a dose-dependent manner with an IC 50 of approximately 10 Ϫ10 M, a value in good agreement with those reported for all melatonin receptors cloned thus far (4-6). The additional 65 amino acid residues of the C-terminal tail present in the reported Mel 1c receptor from dermal melanophores appear not to be involved in G protein coupling because Mel 1c(␣) receptors inhibit forskolin-stimulated cAMP accumulation with the same efficiency as the longer version. This is in agreement with findings from other G protein-coupled receptors where the receptor C terminus is generally not involved in G protein binding (22) .
In contrast, modulation of cAMP levels by melatonin binding to the Mel 1c(␤) receptor appeared to be cell type-dependent. In HeLa and HEK 293 cells, inhibition of adenylyl cyclase activity was similar to that ob- In the family of serpentine, seven membrane-spanning domain receptors, intracellular regions are known to be involved in G protein coupling (22, 24, 25) . Data from signaling experiments in Ltk Ϫ cells suggest that the five amino acid substitutions between Mel 1c(␣) and Mel 1c(␤) receptors, located in the intracellular domains, constitute the molecular basis of the difference in cAMP modulation in these cells.
However, the results of experiments conducted in HeLa and HEK 293 cells indicated that the five amino acid substitutions alone are not sufficient to result in signaling differences in any cellular context. Obviously, cell-specific factors are able to rescue the impaired Mel 1c(␤) receptor signaling. Differences in receptor-G protein interaction are most likely to be responsible for signaling differences. It is now well established that coupling efficiency is governed by the affinity of the G protein for the receptor. Therefore, functional coupling depends on the absolute and relative amounts of G proteins present in the cell and may thus vary from one cell type to another.
The easiest way to explain our results is to assume that Mel 1c receptors are coupled to more than one of the three existing G i protein subtypes to inhibit cAMP accumulation. This assumption is supported by studies of other G i -coupled receptors such as adenosine A1 and 5-hydroxytryptamine 1A (5-HT 1A ) serotonin receptors, which couple to all three G i subtypes although with different affinities (26, 27 Ϫ cells provide a cellular context that reveals differences in signaling capacities of both receptors. These differences might explain why both receptors are expressed in vivo, in X. laevis skin.
The role of cGMP as a second messenger in melatonin receptor signaling is still in discussion. Pigment aggregation in Xenopus melanocytes has been reported to be regulated by melatonin (28) and by cAMP, whereas conflicting results exist on its regulation by cGMP (29, 30) . The role of cGMP in melatonin signaling in other cellular systems has not been deeply investigated so far (2, 3). The notion of cGMP modulation by melatonin receptors also resulted from experiments on neonatal rat pituitary tissue, where an inhibitory effect of melatonin on cGMP production was observed (15 (␣) were higher and the maximal inhibitory effects were lower compared with those measured in cells expressing the Mel 1c(␤) subtype, whereas in Hela cells, modulation of cGMP was at the limit of sensitivity of our assay. These data suggest that Mel 1c(␣) receptors are less efficiently coupled to the cGMP pathway than their allelic counterpart.
Inhibition of cGMP accumulation by melatonin could only be observed when the PDE inhibitor IBMX was included in the incubation medium. IBMX significantly increased basal cGMP levels revealing the existence of a strong basal PDE activity, which maintains low cGMP concentrations under basal conditions. This might explain why melatonin does not inhibit basal cGMP accumulation in the absence of IBMX. Guanylyl cyclases are subdivided into two major families: soluble guanylyl cyclases, which are stimulated by NO, and membrane-bound guanylyl cyclases, which are stimulated by extracellular peptide ligands (31) . Solu-ble guanylyl cyclase seems to be responsible for the cGMP accumulation under basal conditions in the presence of IBMX in HEK 293 cells because this effect was completely inhibited by the soluble guanylyl cyclase-specific inhibitor ODQ (16, 17) . Although agonist stimulation of melatonin receptors inhibits this effect, nitroprusside-stimulated guanylyl cyclase was not directly inhibited by melatonin, suggesting that melatonin receptors interfere upstream of guanylyl cyclase within the cGMP-signaling pathway. The effect of receptor activation on cGMP concentration was abolished by pertussis toxin, indicating that G i/o proteins are involved in the transduction of this signal.
Our data show that cloned high-affinity melatonin receptors may modulate cGMP at physiological concentrations of melatonin. Other receptors of the same family can also control intracellular cGMP levels. The retinal rhodopsin receptor, for example, activates transducin, an heterotrimeric G protein, which, in turn, activates a cGMP-dependent PDE. Transducin binds to inhibitory PDE␥ subunits, causing the activation of ␣-and ␤-catalytic subunits that promote cGMP degradation (32) . Melatonin receptors are likely to activate a different cascade of signaling events because the melatonin signal does not activate a PDE (inhibition of cGMP accumulation is observed in the presence of IBMX). Maura et al. (33, 34) have shown that 5-HT 1D and 5HT 1A serotonin receptors inhibit elevation of glutamate receptor-stimulated cGMP in rat brain cerebellum. Interestingly, inhibition of the cGMP pathway was localized upstream of guanylyl cyclase.
Potential candidates involved in the melatonin receptor-signaling pathway via cGMP are proteins further upstream of guanylyl cyclase such as NO synthase or NO synthase-activators including calmodulin or divalent Ca 2ϩ ions. Other members of the G i/ocoupled receptor subfamily such as somatostatin receptors and the M4 muscarinic receptors have been shown to decrease intracellular Ca 2ϩ levels by inhibiting L-type calcium channels in rat pituitary GH 3 cells (35) . Whether this is also the case for melatonin receptors requires further investigation.
All melatonin receptors cloned so far display high sequence homology and share the capability of inhibiting adenylyl cyclase activity. Therefore, it is tempting to speculate that cGMP modulation is not restricted to Mel 1c subtypes and to Xenopus skin but may have a more general role in melatonin signaling. As a consequence, a new set of downstream effectors, such as cGMP-gated ion channels or cGMP-dependent protein kinases (36) , might be modulated by melatonin. 6 , and DNA polymerase Pwo were purchased from Boehringer Mannheim (Mannheim, Germany). Polyclonal anti Gi-␣ antibodies (Ab84) were a generous gift from Dr. Freissmuth (University of Vienna, Austria).
MATERIALS AND METHODS
Materials
Cloning of Melatonin Receptor cDNAs
Total RNA from X. laevis skin samples was treated for 20 min at 37 C with 0.3 U of RNase-free DNase I (RQ1 DNase, Promega, Madison, WI) per mg nucleic acid. Complementary DNA synthesis was achieved by incubating 200 ng RNA (heated at 65 C for 5 min before the reaction) with 100 U of Moloney murine leukemia virus reverse transcriptase and random primer pd(N) 6 for 30 min at 37 C. After inactivation at 95 C (5 min), cDNA was amplified using appropriate oligonucleotide primers, Pwo DNA polymerase, and PCR buffer provided by the manufacturer in the presence of 2 mM MgSO 4 . DNA was denatured for 2 min at 94 C and then submitted to 40 cycles of temperature (94 C, 15 sec; 30 sec at the optimal primer's temperature; 72 C, 90 sec) followed by 3 min of final extension at 72 C in a GeneAmp PCR System 9600 thermal cycler (Perkin-Elmer Cetus, Norwalk, CT). The following oligonucleotide primers were used for the amplification of various fragments of the X. laevis melatonin receptor cDNA: fragment 1, primer 3S: 5ЈAGAAATGATGGAGGTGAAT-AGCA3Ј and primer 3AS: 5ЈCGGCAATAGACAAACTGA-CAACA3Ј (annealing temperature 54 C); fragment 2, primer 5S: 5ЈTATTGGTCATTTTGTCTGTC and primer 5AS: 5ЈCCAGGT GCTTCTTTGATTAT3Ј (annealing temperature 50 C); fragment 3, primer 6S: 5ЈCTTC AACATAACAGCCAT-AGC3Ј and primer 6AS: 5ЈTGCTTGATTGTTGTTGGTTAC3Ј, (annealing temperature 50 C). The fragment 4, containing the unknown 3Ј-untranslated region, was amplified using the 3Ј-AmpliFINDER RACE kit (CLONTECH, Palo Alto, CA) and the following oligonucleotide primer 11S: 5ЈTATGGTGTGCTA-AATCAAAACTTCCGCAAGG AGTA3Ј and primer 11AS: 5ЈTACTGATGTCCTTATTGACTCCAAGACTGTTGTTT3Ј (annealing temperature 58 C). Finally, the entire melatonin receptor cDNA could be amplified with primer 3S: 5ЈAGAAAT-GATGGAGGTGAATAGCA3Ј and primer 12AS: 5ЈTTAG AATGAATGGACAGAA3Ј (annealing temperature 52 C).
Melatonin receptor cDNAs were cloned in the expression vector pcDNA3/RSV derived from pcDNA3 (Invitrogen, San Diego, CA). The restriction fragment BglII-HindIII of the pcDNA3, containing the cytomegalovirus promoter, was replaced by the corresponding fragment of the pRC/RSV vector (Invitrogen), containing the RSV promoter. Several clones of each receptor were isolated and sequenced by dideoxy sequencing.
Expression of Melatonin Receptor cDNAs
Murine Ltk
Ϫ cells were transfected with melatonin receptor cDNAs as described previously (37) . Human HeLa cells and human embryonic kidney cells (HEK) 293 were transfected by a liposome-mediated transfection method using the transfection reagent DOTAP according to supplier instructions. Neomycin-resistant cells were selected in DMEM supplemented with 10% (vol/vol) FBS, 4.5 g/liter glucose, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM glutamine, and 400 g/ml G418. Individual clones were screened for melatonin binding, using 2-[ 125 I]iodomelatonin as ligand.
For transient expression, Ltk
Ϫ cells were plated on either six-well dishes for cAMP assays (0.5 ϫ 10 6 cells per well) or 10-cm diameter dishes for cGMP assays (2 ϫ 10 6 cells per dish) and transfected with the diethylaminoethyl-dextran method (38) the next day. Briefly, after a washing with PBS, serum-free DMEM, containing 50 mM HEPES, 200 g/ml diethylaminoethyl-dextran, and 1 g/ml plasmid DNA, was added. After incubation at 37 C for 8 h, the medium was replaced by 10% dimethylsulfoxide in serum-free DMEM for 1.5 min. Cells were washed with PBS and then incubated in DMEM containing 10% FCS. Assays were performed 3 days after transfection. Transfection efficiency was around 50% as determined by transfection of ␤-galactosidase cDNA in parallel.
Southern Blot Analysis
Southern blot analysis was performed as described by Jenkins et al. (39) with the following modifications: digested DNA was electrophoresed through 1% agarose gel, Tris-acetate-EDTA 1ϫ, denatured and transferred to Hybond N membranes (Amersham, Arlington Heights, IL) and baked 2 h at 80 C. After a final washing step in 0.1 ϫ NaCl-sodium citrate, 0.01 ϫ SDS for 15 min at 65 C, the membrane was exposed to x-ray film.
Radioligand-Binding Assay
Subconfluent cell monolayers were washed with PBS, incubated for 5 min at 37 C with 2% trypsin-2 mM EDTA, and resuspended in DMEM supplemented with 10% (vol/vol) FBS. After a centrifugation at 450 ϫ g for 5 min at 4 C, cell pellets were resuspended in PBS, pH 7.4. Cell suspensions were incubated with 400 pM 2-[ Binding assays were conducted for 60 min at 25 C in a final reaction volume of 0.25 ml. Reactions were stopped by a rapid filtration through Whatman GF/C glass fiber filters, previously soaked for 30 min in PBS-0.3% polyethyleneimine (to reduce nonspecific binding). Protein concentrations were measured on cell homogenates by the method of Bradford (40) using the Bio-Rad (Bio-Rad Laboratories, Richmond, CA) protein assay system. BSA was used as a standard.
Determination of Intracellular cAMP Levels
Cells grown in six-well dishes were washed twice in serumfree DMEM, preincubated for 15 min at 37 C, and then incubated for 15 min at 37 C in DMEM containing 1 mM IBMX, with or without 10 M isoproterenol (assays on transiently transfected cells) or 10 M forskolin (assays on stable cell clones), and increasing concentrations of melatonin. The incubation buffer was discarded and cells lysed in 1 M NaOH for 20 min at 37 C. After the neutralization of pH with 1 M acetic acid, cell lysates were centrifuged in a microcentrifuge at 17000 ϫ g for 5 min. Supernatants were assayed for cAMP using a [ 3 H]cAMP assay system (Amersham). Alternatively, cAMP assays were performed in 24-well plates (0.5 ϫ 10 6 cells in 300 l). Cells were incubated for 15 min and the reaction terminated by the addition of 100 l 20% trichloracetic acid and supernatants assayed for cAMP using [ 125 I]cAMP tyrosyl methyl ester RIA.
Determination of Intracellular cGMP Levels
Cells grown in 10-cm diameter dishes were incubated at 37 C for 15 min in serum-free DMEM, in the presence or absence of 1 mM IBMX and increasing concentrations of melatonin.
Medium was then replaced by 1 ml of ice-cold 65% ethanol, and cell extracts were centrifuged at 2000 ϫ g for 15 min at 4 C. Supernatants were dried in a speed-vac; pellets were resuspended in 250 l assay buffer, acetylated, and assayed for cGMP, following the instructions of the manufacturer of the enzyme immunoassay kit (Amersham).
Immunoblots of G i Protein ␣ Subunits
Cells were solubilized in Laemmli sample buffer containing 2% SDS and 40 mM dithiothreitol and sonicated at 4 C. After centrifugation in a microcentrifuge at 17,000 ϫ g, 50 l of supernatant were resolved on a 12% SDS/polyacrylamide gel. Immunoblot analysis was carried out as described (13) with the 84 antiserum that labels all three subtypes of G i␣ (data not shown).
